|
Oncogenes and Tumor Suppressors
Citations 191-200 of 795 total displayed.
|
Past content
(since May 2000):
|
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
- Craig Kovitz, Hagop Kantarjian, Guillermo Garcia-Manero, Lynne V. Abruzzo, and Jorge Cortes
Blood 2006; 108: 2811-2813.
[Abstract]
[Full text]
[PDF]
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation
- Hadrian Szpurka, Ramon Tiu, Gurunathan Murugesan, Samer Aboudola, Eric D. Hsi, Karl S. Theil, Mikkael A. Sekeres, and Jaroslaw P. Maciejewski
Blood 2006; 108: 2173-2181.
[Abstract]
[Full text]
[PDF]
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations
- Heather A. Bradeen, Christopher A. Eide, Thomas O'Hare, Kara J. Johnson, Stephanie G. Willis, Francis Y. Lee, Brian J. Druker, and Michael W. Deininger
Blood 2006; 108: 2332-2338.
[Abstract]
[Full text]
[PDF]
Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice
- Chaitali Parikh, Ramesh Subrahmanyam, and Ruibao Ren
Blood 2006; 108: 2349-2357.
[Abstract]
[Full text]
[PDF]
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
- Andres C. Garcia-Montero, Maria Jara-Acevedo, Cristina Teodosio, Maria Luz Sanchez, Rosa Nunez, Aranzazu Prados, Isabel Aldanondo, Laura Sanchez, Mercedes Dominguez, Luis M. Botana, Francisca Sanchez-Jimenez, Karl Sotlar, Julia Almeida, Luis Escribano, and Alberto Orfao
Blood 2006; 108: 2366-2372.
[Abstract]
[Full text]
[PDF]
High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma
- Yun-Wen Chen, Xiao-Tong Hu, Anthony C. Liang, Wing-Yan Au, Chi-Chiu So, Michelle L. Wong, Lijun Shen, Qian Tao, Kent-Man Chu, Yok-Lam Kwong, Raymond H. Liang, and Gopesh Srivastava
Blood 2006; 108: 2373-2383.
[Abstract]
[Full text]
[PDF]
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells
- Lin Qiu, Raymond Lai, Quan Lin, Esther Lau, David M. Thomazy, Daniel Calame, Richard J. Ford, Larry W. Kwak, Robert A. Kirken, and Hesham M. Amin
Blood 2006; 108: 2407-2415.
[Abstract]
[Full text]
[PDF]
CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities
- Young-Jin Lee, Letetia C. Jones, Nikolai A. Timchenko, Danilo Perrotti, Daniel G. Tenen, and Scott C. Kogan
Blood 2006; 108: 2416-2419.
[Abstract]
[Full text]
[PDF]
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
- Michele Baccarani, Giuseppe Saglio, John Goldman, Andreas Hochhaus, Bengt Simonsson, Frederick Appelbaum, Jane Apperley, Francisco Cervantes, Jorge Cortes, Michael Deininger, Alois Gratwohl, François Guilhot, Mary Horowitz, Timothy Hughes, Hagop Kantarjian, Richard Larson, Dietger Niederwieser, Richard Silver, and Rudiger Hehlmann
Blood 2006; 108: 1809-1820.
[Abstract]
[Full text]
[PDF]
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera
- Eric Lippert, Marjorie Boissinot, Robert Kralovics, François Girodon, Irène Dobo, Vincent Praloran, Nathalie Boiret-Dupré, Radek C. Skoda, and Sylvie Hermouet
Blood 2006; 108: 1865-1867.
[Abstract]
[Full text]
[PDF]
|
|
